01—Abstract
Summary
Summary of the 10-K filed March 10, 2009. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported a net loss of $162.9 milliona for 2008 (fiscal year ended January 2, 2009, referred to as calendar 2008), compared with $86.4 million in 2007, and an accumulated deficit of $954.5 million.
Total revenues rose to $117.9 millionb from $113.5 million, while research and development expenses increased to $257.4 million. Management expects losses in 2009 to increase over 2008 and anticipates negative operating cash flow for the foreseeable future. Stockholders' equity was a deficit of $57.0 million at December 31, 2008, down from equity of $72.1 million a year earlier.
The company's most significant development in the period was a worldwide collaboration with Bristol-Myers Squibb, entered into in December 2008, covering XL184 (its most advanced clinical asset, in Phase 3 for medullary thyroid cancer) and XL281. Bristol-Myers Squibb paid an upfront cash payment of $195.0 millionc and is required to pay an additional $45.0 million in 2009. Exelixis will co-develop XL184, funding 35% of development costs with Bristol-Myers Squibb funding 65%, after an initial $100.0 million of combined costs borne by Exelixis, and will share 50% of U.S. commercial profits and losses.
Management stated that it expects to fund operations for at least 12 months following the filing date and aims to operate independently of the capital markets for a substantial period. Liquidity is tight relative to obligations. Cash, equivalents, marketable securities and other restricted or collateralized investments totaled $284.2 milliond at December 31, 2008.
The company owes $102.2 million in principal and accrued interest on a GlaxoSmithKline loan, with the first installment of $28.1 million principal plus interest due in October 2009. The filing describes covenants under the GSK loan and the Deerfield facility (a $150.0 million loan facility, undrawn at year-end) and states that a cash-reserve threshold of $80.0 million tied to the Bristol-Myers Squibb agreement could terminate co-development and co-promotion rights for XL184 if not restored within 90 days.
02—Key points
Key Highlights
- Net loss of $162.9 million for 2008 versus $86.4 million for 2007; accumulated deficit of $954.5 million at year-end.
- Total revenues of $117.9 million in 2008 versus $113.5 million in 2007; research and development expenses rose to $257.4 million from $225.4 million.
- Bristol-Myers Squibb collaboration (December 2008) for XL184 and XL281 includes a $195.0 million upfront payment and $45.0 million in additional license payments due in 2009.
- Cash, equivalents and investments of $284.2 million at December 31, 2008, against a $102.2 million GlaxoSmithKline loan with the first $28.1 million principal installment due October 2009.
- Stockholders' equity was a deficit of $57.0 million at December 31, 2008, compared with equity of $72.1 million at December 31, 2007.
- Restructuring in November 2008 reduced the workforce by 78 employees, or approximately 10%, with a $2.9 million charge recorded.
- Management expects operating losses in 2009 to increase relative to 2008 and anticipates negative operating cash flow for the foreseeable future.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2009filed March 10, 2009Financial Statements
| Revenue | $151.76M |
| R&D Expenses | $234.70M |
| Operating Expenses | $273.67M |
| Operating Income | -$121.91M |
| Interest Expense | $12.67M |
| Net Income | -$135.22M |
| EPS (Basic) | $-1.26 |
| EPS (Diluted) | $-1.26 |
| Shares Outstanding (Basic) | 107.07M |
| Shares Outstanding (Diluted) | 107.07M |
05—Questions
Frequently Asked Questions
Can Exelixis fund its operations without raising new capital?
The company states that its current cash and investments, funds available under the Deerfield Facility Agreement, and expected collaborator funding will enable it to maintain operations for at least 12 months after the filing date. The filing also states that future capital requirements will be substantial and may require earlier use of resources, and that the company may need to raise additional funds, potentially through dilutive equity or debt.
What are the main debt obligations and covenant risks?
The $85.0 million GlaxoSmithKline loan bears 4.0% interest, with $102.2 million of principal and interest outstanding at December 31, 2008, due in three annual installments beginning October 27, 2009. The loan has financial covenants requiring working capital of at least $25.0 million and cash and investments of at least $50.0 million. The filing reports $321.0 million of working capital and $280.2 million of cash and investments under those definitions at year-end. A default under the Deerfield facility could arise if cash and marketable securities fall below $75.0 million at any quarter-end.
What does the Bristol-Myers Squibb XL184 collaboration mean for Exelixis?
Exelixis will co-develop XL184 and share development costs at 35% for Exelixis and 65% for Bristol-Myers Squibb, after Exelixis funds an initial $100.0 million of combined costs. It will share 50% of U.S. commercial profits and losses and has an option to co-promote in the United States. The company may opt out of co-development to receive development and regulatory milestones of up to $295.0 million plus royalties. Co-promotion rights could be terminated if cash reserves fall below $80.0 million and are not restored within 90 days.
What are the key risks to the company's revenue?
The filing states that substantially all revenue has come from collaborative agreements, and that revenue depends on continued collaborations, milestone achievement and royalties. Bristol-Myers Squibb, GlaxoSmithKline and Genentech accounted for 46%, 37% and 17% of 2008 revenues, respectively. Several agreements contain early termination provisions, and the company has no approved pharmaceutical products or product revenues to date.
06—Continue